» Articles » PMID: 34469110

Discovery of Highly Potent Adenosine A Receptor Agonists: Targeting Positron Emission Tomography Probes

Abstract

Adenosine receptor (AR) radiotracers for positron emission tomography (PET) have provided knowledge on the biodistribution of ARs in the central nervous system (CNS), which is of therapeutic interest for various neuropsychiatric disorders. Additionally, radioligands that can image changes in endogenous adenosine levels in different physiological and pathological conditions are still lacking. The binding of known antagonist adenosine A receptor (AR) radiotracer, [C]MDPX, failed to be inhibited by elevated endogenous adenosine in a rodent PET study. Since most of the known AR PET radiotracers were antagonists, we propose that an AR agonist radioligand may possess higher sensitivity to measure changes in endogenous adenosine concentration. Herein, we report our latest findings toward the development of a full agonist adenosine A radioligand for PET. Based on a 3,5-dicyanopyridine template, 16 new derivatives were designed and synthesized to optimize both binding affinity and functional activity, resulting in two full agonists (compounds and ) with single-digit nanomolar affinities and good subtype selectivity (A/A selectivity of ∼1000-fold for compound and 29-fold for compound ). Rapid O-[C]methylation provided [C] and [C] in high radiochemical yields and radiochemical purity. However, subsequent brain PET imaging in rodents showed poor brain permeability for both radioligands. An PET study using knockout mice for MDR 1a/a, BCRP, and MRP1 indicated that these compounds might be substrates for brain efflux pumps. In addition, evaluation using multiparameter optimization identified high molecular weight and high polar surface area as the main molecular descriptors responsible for low brain penetration. These results will provide further insight toward development of full agonist adenosine A radioligands and also highly potent CNS AAR drugs.

Citing Articles

New paradigms in purinergic receptor ligand discovery.

Jacobson K, Pradhan B, Wen Z, Pramanik A Neuropharmacology. 2023; 230:109503.

PMID: 36921890 PMC: 10233512. DOI: 10.1016/j.neuropharm.2023.109503.


Discovery and Structure-Activity Relationship Studies of Novel Adenosine A Receptor-Selective Agonists.

Preti B, Suchankova A, Deganutti G, Leuenberger M, Barkan K, Manulak I J Med Chem. 2022; 65(21):14864-14890.

PMID: 36270633 PMC: 9661479. DOI: 10.1021/acs.jmedchem.2c01414.

References
1.
Herrera C, Casado V, Ciruela F, Schofield P, Mallol J, Lluis C . Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells. Mol Pharmacol. 2000; 59(1):127-34. View

2.
Jacobson K, Tosh D, Jain S, Gao Z . Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development. Front Cell Neurosci. 2019; 13:124. PMC: 6447611. DOI: 10.3389/fncel.2019.00124. View

3.
Paul S, Khanapur S, Rybczynska A, Kwizera C, Sijbesma J, Ishiwata K . Small-animal PET study of adenosine A(1) receptors in rat brain: blocking receptors and raising extracellular adenosine. J Nucl Med. 2011; 52(8):1293-300. DOI: 10.2967/jnumed.111.088005. View

4.
Catarzi D, Varano F, Varani K, Vincenzi F, Pasquini S, Dal Ben D . Amino-3,5-Dicyanopyridines Targeting the Adenosine Receptors Ranging from Pan Ligands to Combined A/A Partial Agonists. Pharmaceuticals (Basel). 2019; 12(4). PMC: 6958422. DOI: 10.3390/ph12040159. View

5.
Louvel J, Guo D, Agliardi M, Mocking T, Kars R, Pham T . Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines. J Med Chem. 2014; 57(8):3213-22. DOI: 10.1021/jm401643m. View